NASDAQ:LIFE

aTyr Pharma Stock Forecast, Price & News

$3.92

-0.04 (-1.01 %)

(As of 01/21/2021 03:59 PM ET)

Add

Compare

Today's Range

$3.85

Now: $3.92▼

$3.98

50-Day Range

$3.72

MA: $4.15▼

$4.66

52-Week Range

$2.13

Now: $3.92▼

$7.27

Volume12,499 shs

Average Volume508,069 shs

Market Capitalization$39.93 million

P/E RatioN/A

Dividend YieldN/A

Beta2.17

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial. The company has a collaboration with the University of Nebraska Medical Center for the development of NRP2 biology; research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases; and research collaboration with Boston Children's Hospital. It also has license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan; and a research collaboration with the Medical University of South Carolina to develop therapeutic antibodies that selectively target specific NRP2 isoforms. The company was founded in 2005 and is headquartered in San Diego, California.

MarketRank^™

Overall MarketRank^™

1.45 out of 5 stars

Medical Sector

479th out of 1,926 stocks

Biological Products, Except Diagnostic Industry

61st out of 177 stocks

3.5 Analyst's Opinion

Consensus Rating
aTyr Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.00, aTyr Pharma has a forecasted upside of 204.6% from its current price of $3.94.
Amount of Analyst Coverage
aTyr Pharma has received no research coverage in the past 90 days.

2.3 Community Rank

Outperform Votes
aTyr Pharma has received 388 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
aTyr Pharma has received 449 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
aTyr Pharma has received 53.64% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote “Outperform” if you believe LIFE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LIFE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
aTyr Pharma does not currently pay a dividend.
Dividend Growth
aTyr Pharma does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, aTyr Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.44% of the stock of aTyr Pharma is held by insiders.
Percentage Held by Institutions
55.82% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for aTyr Pharma are expected to decrease in the coming year, from ($2.14) to ($2.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of aTyr Pharma is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of aTyr Pharma is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
aTyr Pharma has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryLife Sciences Tools & Services

SectorMedical

Current SymbolNASDAQ:LIFE

Previous Symbol

CUSIP53217V10

CIK1339970

Webwww.atyrpharma.com

Phone858-731-8389

Employees39

Debt

Debt-to-Equity RatioN/A

Current Ratio4.76

Quick Ratio4.76

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$420,000.00

Price / Sales95.06

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.40 per share

Price / Book0.73

Profitability

EPS (Most Recent Fiscal Year)($7.03)

Net Income$-23,600,000.00

Net Margins-202.02%

Return on Equity-52.75%

Return on Assets-38.40%

Miscellaneous

Outstanding Shares10,185,000

Market Cap$39.93 million

Next Earnings Date3/25/2021 (Estimated)

OptionableOptionable

$3.92

-0.04 (-1.01 %)

(As of 01/21/2021 03:59 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive LIFE News and Ratings via Email

Sign-up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter.

aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions

How has aTyr Pharma's stock been impacted by Coronavirus (COVID-19)?

aTyr Pharma's stock was trading at $3.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, LIFE shares have increased by 31.4% and is now trading at $3.98.
View which stocks have been most impacted by COVID-19.

Is aTyr Pharma a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" aTyr Pharma stock.
View analyst ratings for aTyr Pharma or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than aTyr Pharma?

Wall Street analysts have given aTyr Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but aTyr Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as aTyr Pharma's CEO?

1,448 employees have rated aTyr Pharma CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among aTyr Pharma's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is aTyr Pharma's next earnings date?

aTyr Pharma is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021.
View our earnings forecast for aTyr Pharma.

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:LIFE) announced its quarterly earnings results on Tuesday, November, 17th. The biotechnology company reported ($0.68) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.74) by $0.06. The biotechnology company had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.16 million. aTyr Pharma had a negative return on equity of 52.75% and a negative net margin of 202.02%.
View aTyr Pharma's earnings history.

When did aTyr Pharma's stock split? How did aTyr Pharma's stock split work?

Shares of aTyr Pharma reverse split before market open on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 28th 2019. An investor that had 100 shares of aTyr Pharma stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for LIFE?

3 Wall Street analysts have issued twelve-month price targets for aTyr Pharma's stock. Their forecasts range from $8.00 to $15.00. On average, they expect aTyr Pharma's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 201.5% from the stock's current price.
View analysts' price targets for aTyr Pharma or view Wall Street analyst' top-rated stocks.

Are investors shorting aTyr Pharma?

aTyr Pharma saw a increase in short interest in December. As of December 31st, there was short interest totaling 105,500 shares, an increase of 157.3% from the December 15th total of 41,000 shares. Based on an average daily trading volume, of 567,300 shares, the short-interest ratio is currently 0.2 days.
View aTyr Pharma's Short Interest.

Who are some of aTyr Pharma's key competitors?

Some companies that are related to aTyr Pharma include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Waters (WAT), Charles River Laboratories International (CRL), Bio-Techne (TECH), Bruker (BRKR), Pacific Biosciences of California (PACB), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO) and BG Medicine (BGMD).
View all of LIFE's competitors.

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

Who are aTyr Pharma's key executives?

aTyr Pharma's management team includes the following people:

Dr. Sanjay S. Shukla, Pres, CEO & Director (Age 48, Pay $555.7k)
Ms. Jill M. Broadfoot, Chief Financial Officer (Age 58, Pay $421.09k)
Ms. Nancy E. Denyes Krueger, Gen. Counsel & Corp. Sec. (Age 52, Pay $434.28k)
Xiang-Lei Yang Ph.D., Founder
Mr. Peter Villiger, VP of Corp. Devel.
Dr. Ying J. Buechler, Exec. Director of Biologics Devel. & Manufacturing
Dr. Melissa A. Ashlock, Sr. Advisor (Age 62)
Dr. David J. King, Scientific Consultant (Age 61)

When did aTyr Pharma IPO?

(LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

How do I buy shares of aTyr Pharma?

Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is aTyr Pharma's stock price today?

One share of LIFE stock can currently be purchased for approximately $3.98.

How big of a company is aTyr Pharma?

aTyr Pharma has a market capitalization of $40.54 million and generates $420,000.00 in revenue each year. The biotechnology company earns $-23,600,000.00 in net income (profit) each year or ($7.03) on an earnings per share basis. aTyr Pharma employs 39 workers across the globe.

What is aTyr Pharma's official website?

The official website for aTyr Pharma is www.atyrpharma.com.

How can I contact aTyr Pharma?

aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-731-8389 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here